Merck And Teva May Forgo Trial Over Actonel
The latest round in Merck & Co.'s long-running patent battle with generics maker Teva over bone strengthening compounds may end with a whimper rather than a bang, after both sides reportedly...To view the full article, register now.
Already a subscriber? Click here to view full article